Biological Safety Testing Products and Services Market Report 2026

The biological safety testing products and services market size has grown rapidly in recent years. It will grow from $6.12 billion in 2025 to $6.93 billion in 2026 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to rising production of vaccines and biologics, expansion of pharmaceutical manufacturing capacity, increasing regulatory scrutiny on product safety, wider adoption of cell and gene therapies, growth of clinical research activities.

The biological safety testing products and services market size is expected to see rapid growth in the next few years. It will grow to $11.34 billion in 2030 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to increasing demand for advanced biologics safety assays, rising investments in automated testing platforms, expansion of gene and cell therapy pipelines, growing need for faster release testing, increasing emphasis on contamination risk mitigation. Major trends in the forecast period include increasing adoption of rapid microbial detection methods, rising demand for automated sterility testing systems, growing use of pcr-based safety testing, expansion of outsourced biological testing services, enhanced focus on regulatory-compliant testing solutions.

The rising demand for gene therapies is anticipated to drive the growth of the biological safety testing products and services market in the coming years. Gene therapy is a medical technique that employs genes to treat or prevent diseases by replacing, modifying, or supplementing defective genes. Increased investment and research on gene mutations, along with supportive regulatory frameworks, further foster innovation and broaden the applications of gene therapies. Biological safety testing products and services in gene therapy ensure that viral vectors and genetic materials are free from contaminants and safe for use. For example, in January 2024, according to a published report by the American Society of Gene & Cell Therapy, a US-based non-profit medical and scientific organization, in the fourth quarter of 2023, the number of gene therapies in Phase III clinical trials increased by 10%, marking the first quarterly rise of this kind since the third quarter of 2022. Consequently, the growing demand for gene therapies propels the market for biological safety testing products and services.

Major companies in the biological safety testing products and services market are focusing on developing rapid animal-free bacterial endotoxin testing to improve patient safety and accelerate drug development. This innovative method seeks to shorten testing time and increase reliability without relying on animal-based products. For example, in January 2024, Charles River Laboratories International, a US-based pharmaceutical and biotechnology company, launched the Endosafe Trillium cartridge, which uses recombinant technology to detect and quantify endotoxins without animal-derived materials. It is the first rapid animal-free bacterial endotoxin test offering a faster turnaround time and eliminating the need for animal-derived reagents, thereby promoting sustainability and ethical testing practices. This product is designed to deliver rapid, accurate results while reducing dependence on the traditional Limulus amebocyte lysate (LAL) sourced from horseshoe crabs.

In September 2023, Technical Safety Services, a US-based biotechnology company, acquired Controlled Environment Management LLC for an undisclosed sum. The acquisition is intended to strengthen TSS's support for pharmaceutical, biotechnology, and healthcare clients by broadening its geographic reach and service offerings. Controlled Environment Management LLC is a US-based company that delivers services critical for biological safety testing, including testing, validation, certification, and calibration of controlled environments.

Major companies operating in the biological safety testing products and services market are Merck KGaA, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, SGS Société Générale de Surveillance SA, Eurofins Scientific, Agilent Technologies Inc., Lonza Group AG, WuXi AppTec Co. Ltd., Charles River Laboratories Inc., BioMérieux SA, Almac Group, Samsung Biologics Co. Ltd., Maravai LifeSciences Holdings Inc., Genscript Biotech Corp, Wako Pure Chemical Industries Ltd., Associates of Cape Cod Inc., InvivoGen S.A.S., Microcoat Biotechnologie GmbH, BSL BIOSERVICE Scientific Laboratories Munich GmbH, Redberry, PathoQuest.

North America was the largest region in the biological safety testing products and services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biological safety testing products and services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biological safety testing products and services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the biological safety testing products and services market by increasing the cost of imported reagents, assay kits, analytical instruments, and automated testing systems used across sterility, endotoxin, and adventitious agent detection. North America and Europe are most affected due to reliance on imported high-precision laboratory equipment, while Asia-Pacific faces cost pressure on consumables and reagents. These tariffs are raising operational costs for testing laboratories and biopharmaceutical manufacturers. However, they are also encouraging local production of reagents, regional instrument manufacturing, and domestic expansion of testing service providers, strengthening supply chain resilience.

The biological safety testing products and services market research report is one of a series of new reports that provides biological safety testing products and services market statistics, including biological safety testing products and services industry global market size, regional shares, competitors with a biological safety testing products and services market share, detailed biological safety testing products and services market segments, market trends and opportunities, and any further data you may need to thrive in the biological safety testing products and services industry. This biological safety testing products and services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biological safety testing products and services encompass equipment and techniques used to verify that biological products are safe and free from harmful contaminants, ensuring their effectiveness and safety for medical applications. Their main objective is to identify and prevent contamination from bacteria, viruses, fungi, and other pathogens.

The primary products and services in biological safety testing include reagents and kits, instruments, and services. Reagents and kits consist of various chemicals, enzymes, antibodies, and other materials used to detect and quantify contaminants, pathogens, or impurities in biological products. The different test types include endotoxin tests, sterility tests, cell line authentication and characterization tests, bioburden tests, adventitious agent detection tests, residual host contamination detection tests, and others, which are applied across vaccines and therapeutics, blood and blood-based products, gene therapy, tissue and tissue-based products, and stem cells.

The biological safety testing product and services market consists of revenues earned by entities by providing services such as viral clearance studies, environmental monitoring, toxicology testing, and batch release testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The biological safety testing market also includes sales of polymerase chain reaction (PCR) machines, biosafety cabinets, autoclaves, and centrifuges. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.